DIVIS LABORATORIES
Back to Income Statement
|
DIVIS LABORATORIES Last 5 Year Consolidated Net Profit History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Consolidated Net Profit | ₹1,600 Cr | ₹1,824 Cr | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr |
What is the latest Consolidated Net Profit of DIVIS LABORATORIES ?
Year | Consolidated Net Profit |
---|---|
Mar2024 | ₹1,600 Cr |
Mar2023 | ₹1,824 Cr |
Mar2022 | ₹2,960 Cr |
Mar2021 | ₹1,984 Cr |
Mar2020 | ₹1,377 Cr |
How is Consolidated Net Profit of DIVIS LABORATORIES Trending?
Years | Consolidated Net Profit | % Change | |
---|---|---|---|
Mar2024 | ₹1,600 Cr | -12.28 | |
Mar2023 | ₹1,824 Cr | -38.39 | |
Mar2022 | ₹2,960 Cr | 49.19 | |
Mar2021 | ₹1,984 Cr | 44.15 | |
Mar2020 | ₹1,377 Cr | - |
Compare Consolidated Net Profit of peers of DIVIS LABORATORIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
DIVIS LABORATORIES | ₹163,028.9 Cr | 4.3% | 6.5% | 63.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹419,764.0 Cr | 0.6% | -2.1% | 16.5% | Stock Analytics | |
CIPLA | ₹118,905.0 Cr | 3.6% | 0.2% | 2.3% | Stock Analytics | |
MANKIND PHARMA | ₹103,904.0 Cr | -2.5% | -8% | 16.5% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,523.0 Cr | 3% | -8.4% | 0% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,015.0 Cr | 3.2% | -1% | 27.4% | Stock Analytics |
DIVIS LABORATORIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
DIVIS LABORATORIES | 4.3% |
6.5% |
63.9% |
SENSEX | 0.5% |
0.3% |
7.9% |
You may also like the below Video Courses